This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Big Cure For 2013 - Research Report On Biogen Idec Inc. And Keryx Biopharmaceuticals Inc.

NEW YORK, January 23, 2013 /PRNewswire/ --

Biogen Idec Inc. (NASDAQ:BIIB) [ Full Research Report] [1] and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) [ Free Research Report] [ 2 ] both announced that marketing approvals are underway for their respective treatments, recombinant factor IX Fc fusion protein (rFIXFC) and Zerenex. Biogen's rFIXFC is the first product candidate in a new class of long-lasting clotting factor therapy for the treatment of hemophilia B. Keryx' Zerenex (ferric citrate) is an oral, iron-based compound for the treatment of kidney disease.

After separate disappointing news from Biogen and Keryx regarding the failure of their previous drug treatments for ALS and colorectal cancer, their good news this year are expected to push their sales and trading volumes to record-highs. Analysts are bullish that both companies can rake in significant revenues to brighten the shine of the lackluster biopharmaceutical industry. The probability of success is still not solid for Biogen or Keryx, but the positive outlook towards sales forecasts and stock advances for each company remains strong. Until the FDA green lights the marketing of both drugs can everyone be certain of a new reason to celebrate.

The huge factor which clouds the issue of size is the bull inflection which analysts and investors stood by during the toughest of times. Despite the huge risk when it comes to research and development, neither Biogen nor Keryx is at risk of suffering a tragic downfall. For instance, the risk of Keryx in going bankrupt is surprisingly close to none compared to its risk of getting disappointing results from phase 3 trials. It seems too hard to believe, but the development stage company actually gets royalty payments from its Japanese partner, JT Torii, every time it climbs a notch up the ladder. This is a good way for the company to cope with its run rate.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs